Product image of Neisvac-C (Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated)) supplied by GNH India

Neisvac-C

Active Ingredient:
Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated)
Origin:
EU

Neisvac-C (Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated))

Tetanus toxoid, algeldrate, Neisseria meningitidis group C polysaccharide, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It provides active immunity against tetanus and meningococcal group C disease in individuals at risk.

Originating from the European Union, GNH India supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pfizer S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neisvac-C is used to stimulate protective immunity against tetanus toxin and the capsular polysaccharide of Neisseria meningitidis group C.

  • Tetanus: Provides active protection against tetanus in individuals without adequate immunity.
  • Meningococcal group C disease: Induces antibodies that help prevent invasive disease caused by Neisseria meningitidis group C.
  • Post‑exposure prophylaxis for tetanus: Used as part of the recommended regimen to prevent tetanus after potential wound contamination.

How It Works

  • Neisvac-C induces active immunity by presenting tetanus toxoid and the de‑O‑acetylated capsular polysaccharide of Neisseria meningitidis group C to the immune system, prompting B‑cell activation and the production of specific antibodies that neutralize tetanus toxin and target the meningococcal capsule, thereby conferring protection against both pathogens.

Side Effects

Neisvac-C may be associated with local and systemic reactions following intramuscular administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the site of injection.
  • Redness and swelling: localized erythema and edema.
  • Fever: transient low‑grade temperature rise.
  • Headache: mild headache occurring within 24 hours.
  • Fatigue: temporary feeling of tiredness.
  • Myalgia: muscle aches around the injection area.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with ascending weakness.
  • Seizures: infrequent occurrence, especially in individuals with pre‑existing conditions.
  • Hypotension: sudden drop in blood pressure post‑vaccination.

Precautions & Warnings

Before administering Neisvac-C, healthcare professionals should consider the following precautions.

  • Allergy assessment: Verify no known hypersensitivity to tetanus toxoid, algeldrate, or meningococcal polysaccharide.
  • Acute illness: Defer vaccination in persons with moderate or severe febrile illness until recovery.
  • Immunocompromised patients: Use with caution, as response may be reduced.
  • Concomitant vaccines: Observe recommended intervals when given with other live vaccines.
  • Pregnancy and lactation: Evaluate risk‑benefit; limited data available.
  • Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Neisvac-C can interact with other agents, influencing immune response or safety.

Major Interactions (Avoid)

  • Live attenuated vaccines: Avoid simultaneous administration to prevent interference with immune response.
  • Immunoglobulin therapy: Do not give within 2 weeks before or after vaccination as it may diminish antibody production.

Moderate Interactions (Monitor Closely)

  • Other inactivated vaccines: May be co‑administered but monitor for increased reactogenicity.
  • Antipyretics: Prophylactic acetaminophen may reduce antibody response; consider timing.
  • Immunosuppressive drugs: May lower vaccine efficacy; assess need for revaccination.

Frequently Asked Questions

Neisvac-C is a combination vaccine indicated for the prevention of tetanus and for protection against invasive disease caused by Neisseria meningitidis group C. It is administered to individuals who need immunity to both pathogens, such as travelers, adolescents, and adults lacking adequate prior vaccination.

The vaccine contains tetanus toxoid and a de‑O‑acetylated polysaccharide from Neisseria meningitidis group C. These components stimulate the immune system to produce specific antibodies that neutralize tetanus toxin and target the bacterial capsule, providing active, long‑lasting protection against both infections.

The dosing schedule for Neisvac-C is determined by the prescribing clinician based on age, immunization history, and risk factors. Typically, a single intramuscular injection is given, with booster doses recommended according to national immunization guidelines.

Data on the use of Neisvac-C in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits of preventing tetanus and meningococcal disease against any unknown risks, and may consider vaccination when the benefits outweigh potential concerns.

To order Neisvac-C, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Neisvac-C combines tetanus toxoid with a group C meningococcal polysaccharide, offering dual protection in a single injection. Compared with separate tetanus‑only or meningococcal‑only vaccines, it reduces the number of injections required but may have a reactogenicity profile similar to other conjugate‑type polysaccharide vaccines.

Neisvac-C must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, inspect the solution for clarity; do not use if the product appears discolored or contains particles.

Neisvac-C is administered as a single intramuscular injection, usually into the deltoid muscle of adults or the anterolateral thigh in younger children, following aseptic technique. The injection should be performed by a qualified healthcare professional.

The most serious adverse events associated with Neisvac-C include severe allergic reactions such as anaphylaxis, rare neurological conditions like Guillain‑Barré syndrome, and, very rarely, seizures or sudden hypotension. Immediate medical attention is required if any of these symptoms occur after vaccination.

Neisvac-C should not be given to individuals with a known hypersensitivity to tetanus toxoid, algeldrate, or the meningococcal group C polysaccharide. It is also contraindicated in persons who have experienced a severe allergic reaction to a previous dose of the same vaccine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT